Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Immunome (IMNM) Return on Equity: 2023-2025

Historic Return on Equity for Immunome (IMNM) over the last 2 years, with Sep 2025 value amounting to -0.88%.

  • Immunome's Return on Equity rose 48.00% to -0.88% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.88%, marking a year-over-year increase of 48.00%. This contributed to the annual value of -2.03% for FY2024, which is N/A change from last year.
  • Immunome's Return on Equity amounted to -0.88% in Q3 2025, which was down 12.73% from -0.78% recorded in Q2 2025.
  • Over the past 5 years, Immunome's Return on Equity peaked at -0.78% during Q2 2025, and registered a low of -1.74% during Q4 2023.
  • Its 3-year average for Return on Equity is -1.17%, with a median of -1.09% in 2024.
  • Data for Immunome's Return on Equity shows a peak YoY skyrocketed of 48bps (in 2025) over the last 5 years.
  • Over the past 3 years, Immunome's Return on Equity (Quarterly) stood at -1.74% in 2023, then rose by 19bps to -1.54% in 2024, then soared by 48bps to -0.88% in 2025.
  • Its Return on Equity stands at -0.88% for Q3 2025, versus -0.78% for Q2 2025 and -0.89% for Q1 2025.